GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis

University Hospital, Gentofte, Copenhagen

Status: Unknown

Conditions: Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI

Treatments: Drug: Liraglutide; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01451905

GLP1-PSO

Details and patient eligibility

About

To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease

Enrollment: 12 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

4.3 Inclusion Criteria

• Caucasians above 18 years of age
• Plaque psoriasis
• PASI score >10
• No treatment or stable treatment of psoriasis during at least 3 months before inclusion
• Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2
• Normal blood pressure
• Spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (~5 times the plasma half-life) 4.4 Exclusion Criteria
• Psoriasis arthritis
• Fasting plasma glucose > 7.5 mmol/L or HbA1c > 7.5%
• Type 1 diabetes
• Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists)
• Heart failure, NYHA class III-IV
• Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine >150 µM and/or albuminuria
• Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) >2 x upper normal serum levels)
• Anaemia
• Acute or chronic pancreatitis
• Struma or thyroid cancer
• Pregnancy or breast feeding
• Inability to complete the study

Trial design

12 participants in 2 patient groups, including a placebo group

Psoriasis

Active Comparator group

Treatment:

Drug: Liraglutide

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo